Advertisement

Effects of BIBR-277, an Angiotensin-II Type-1 Receptor Antagonist, on Ischemic Myocardial Stunning in Dogs

  • Tohru Nakai
  • Kumi Satoh
  • Atsuko Yamamoto
  • Katsuji Hoshi
  • Kazuo Ichihara
Part of the Progress in Experimental Cardiology book series (PREC, volume 1)

Abstract

BIBR-277, an angiotensin-II type-1 receptor antagonist, improved the recovery of contractile function of the stunned myocardium. Enalapril also lessened the contractile dysfunction during reperfusion in the stunned myocardium. These drugs may act to reduce ischemic damage by removing the systemic and coronary vasoconstrictive effects of angiotensin II.

Keywords

Left Anterior Descend Coronary Flow Saline Group Stun Myocardium Angiotensin Receptor Antagonist 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Valloton MB. 1987. The renin-angiotensin system. Trends Pharmacol Sci 8:69–74.CrossRefGoogle Scholar
  2. 2.
    Mcalpine HM, Cobbe SM. 1988. Neuroendocrine change in acute myocardial infarction. Am J Med 84(Suppl 3A):61–66.PubMedCrossRefGoogle Scholar
  3. 3.
    Liang C, Gavras H, Black J, Sherman LG, Hood WB. 1982. Renin-angiotensin system inhibition in acute myocardial infarction in dogs. Effects on systemic hemodynamics, mycoardial blood flow, segmental myocardial function and infarct size. Circulation 66:1249–1255.PubMedGoogle Scholar
  4. 4.
    Katoh Y, Komuro I, Shibasaki Y, Yamaguchi H, Yazaki Y. 1989. Angiotensin II induces hypertrophy and oncogene expression in cultured rat heart myocytes. Circulation 80(Suppl II):II–450.Google Scholar
  5. 5.
    Gavras H, Kremer D, Brown JJ. 1975. Angiotensin and norepinephrine induced myocardial lesions; experimental and clinical studies in rabbits and man. Am Heart J 89:321–332.PubMedCrossRefGoogle Scholar
  6. 6.
    Packer M. 1987. Converting enzyme inhibition in the management of severe chronic congestive heart failure: physiologic concept. J Cardiovasc Pharmacol 10(Supp1 7):S83–S87.PubMedGoogle Scholar
  7. 7.
    Robertoson JIS, Tillman DM, 1987. Converting enzyme inhibitors in the treatment of hypertension. J Cardiovasc Pharmacol 10(Suppl 7):S43–S48.CrossRefGoogle Scholar
  8. 8.
    Ertl G. 1988. Angiotensin converting enzyme inhibitors and ischaemic heart disease. Eur Heart J 9:716–727.PubMedGoogle Scholar
  9. 9.
    Okunishi H, Miyazaki M, Okamura T, Toda N. 1987. Different distribution of two types of angiotensin-generating enzymes in the aortic wall. Biochem Biophys Res Commun 149:1186–1192.PubMedCrossRefGoogle Scholar
  10. 10.
    Kinoshita A, Uratu H, Bunpus FM, Husain A. 1991. Multiple determinants for the high substrate specificity of an angiotensin II-forming chymase from human heart. J Biol Chem 266:19192–19197.PubMedGoogle Scholar
  11. 11.
    Wienen W, Hauel N, Van Meel JCA, Narr B, Ries U, Entzeroth M. 1993. Pharmacological characterization of the novel nonpeptide angiotensin II receptor antagonist, BIBR 277. Br J Pharmacol 110:245–252.PubMedGoogle Scholar
  12. 12.
    Izumi H, Nakai T, Kano S, Hoshi K, Ichihara K. 1996. Effects of BIBR-277, an angiotensin II type 1 receptor antagonist, on stunned myocardium in dogs. Coronary Artery Dis 7:775–779.CrossRefGoogle Scholar
  13. 13.
    Sirett NE, Bray JJ, Hubbard JI. 1981. Localization of immunoreactive angiotensin II in the hippocampus and striatum of rat brain. Brain Res 217:405–411.PubMedCrossRefGoogle Scholar
  14. 14.
    Koch-Weser J. 1964. Myocardial actions of angiotensin. Circ Res 14:337–344.PubMedGoogle Scholar
  15. 15.
    Blumberg AL, Ackerly JA, Peach MJ. 1975. Differentiation of neurogenic and myocardial angiotensin II receptors in isolated rabbit atria. Circ Res 36:719–726.PubMedGoogle Scholar
  16. 16.
    Miwa K, Toda N. 1984. Regonal differences in the response to vasoconstrictor agents of dog and monkey isolated coronary arteries. Br J Pharmacol 82:295–301.PubMedGoogle Scholar
  17. 17.
    Yoshiyama M, Kim S, Yamagishi H, Omura T, Tani T, Yanagi S, Toda I, Teragaki M, Akioka K, Takeuchi K, Takeda T. 1994. Cardioprotective effect of the angiotensin II type 1 receptor antagonist TCV-116 on ischemia-reperfusion injury. Am Heart J 128:1–6.PubMedCrossRefGoogle Scholar
  18. 18.
    Gavras H, Brown JJ, Lever M, Macadam RF, Robertson JIS. 1971. Acute renal failure, tubular necrosis, and myocardial infarction induced in the rabbit by intravenous angiotensin II. Lancet 2:19–22.PubMedCrossRefGoogle Scholar
  19. 19.
    Tan L-B, Jalil JE, Pick R, Janicki JS, Weber KT. 1991. Cardiac myocyte necrosis induced by angiotensin II. Circ Res 69:1185–1195.PubMedGoogle Scholar
  20. 20.
    Brown K. 1989. Angiotensin receptors are implicated in the mechanism of mass action. Trends Pharmacol Sci 10:87–89.PubMedCrossRefGoogle Scholar
  21. 21.
    Gondo M, Maruta H, Arakawa K. 1989. Direct formation of angiotensin II without renin or converting enzyme in the ischemic dog heart. Jpn Heart J 30:219–229.PubMedGoogle Scholar
  22. 22.
    Noda K, Sasaguri M, Ideishi M, Ikeda M, Arakawa K. 1993. Role of locally formed angiotensin II and bradykinin in the reduction of myocardial infarct size in dogs. Cardiovasc Res 27:334–340.PubMedCrossRefGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1998

Authors and Affiliations

  • Tohru Nakai
    • 1
  • Kumi Satoh
    • 1
  • Atsuko Yamamoto
    • 1
  • Katsuji Hoshi
    • 1
  • Kazuo Ichihara
    • 1
  1. 1.Hokkaido College of PharmacyJapan

Personalised recommendations